Inhaled corticosteroids in COPD: friend or foe?
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …
Impact and prevention of severe exacerbations of COPD: a review of the evidence
DMG Halpin, M Miravitlles, N Metzdorf… - International journal of …, 2017 - Taylor & Francis
Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …
implications for patients and significant economic consequences for society. The prevalence …
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary
CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
[HTML][HTML] Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Background Patients with chronic obstructive pulmonary disease (COPD) with an
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease …
S Pascoe, N Locantore, MT Dransfield… - The lancet Respiratory …, 2015 - thelancet.com
Background The short-term benefits of inhaled corticosteroids for patients with chronic
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the …
H Watz, K Tetzlaff, EFM Wouters, A Kirsten… - The lancet Respiratory …, 2016 - thelancet.com
Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS)
in patients with chronic obstructive pulmonary disease (COPD) and a history of …
in patients with chronic obstructive pulmonary disease (COPD) and a history of …
FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease
DA Lipson, H Barnacle, R Birk, N Brealey… - American journal of …, 2017 - atsjournals.org
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
[HTML][HTML] Withdrawal of inhaled glucocorticoids and exacerbations of COPD
H Magnussen, B Disse… - … England Journal of …, 2014 - Mass Medical Soc
Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
S Pascoe, N Barnes, G Brusselle… - The Lancet …, 2019 - thelancet.com
Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …